Regentis (RGNT) Director Efraim Cohen-Arazi Receives Option Award

What Happened
Efraim Cohen-Arazi, a director of Regentis Biomaterials Ltd. (RGNT), received a grant of 24,826 derivative securities on July 9, 2026. The grant shows $0.00 paid at grant (an option/award, not an open‑market purchase or sale). No immediate cash value was paid in the filing.

Key Details

• Transaction date: July 9, 2026; Form 4 filed July 13, 2026 (filed within the two-business-day deadline).
• Transaction type: Award/Grant (code A) — 24,826 options/derivative securities at $0.00.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes of note:
  • Board approved the grant May 28, 2026; shareholder approval was obtained July 9, 2026 (F1).
  • Vesting: 1/12 vests on Aug 28, 2026, then one‑twelfth each three months thereafter, fully vesting on May 28, 2029, subject to continued service (F2).
  • To qualify for Israeli Section 102 tax benefits, securities must be registered in the name of a trustee (F3).
• No exercise price or immediate intrinsic value is listed in the provided summary.

Context
This filing reports an equity award (options) rather than a purchase or sale — it does not represent shares changing hands on the open market. Options vest over time and only become actionable according to the vesting and any plan/exercise terms; the filing does not state whether shares can be sold immediately upon vesting. Awards to directors are common as compensation and do not by themselves indicate a buy/sell signal.